A range of vaccine approaches are being tested in early phase clinical trials. This table provides highlights of this area of vaccine research.
Additional Vaccine Approaches
Vaccine Research Developing Programs
This graphic provides a state of the field on vaccine research development programs, giving details on the Pox-Protein Public-Private Partnership trials testing canarypox-protein based vaccine candidates and the Jannssen development program of Ad26 vector + Mosaic immunogen vaccine strategy.
After FACTS: What’s next for HIV prevention in women?
FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. In this webinar, we discussed what these and other data meant for women, including young and adolescent girls.
AVAC Report 2014/15: HIV Prevention on the Line
In AVAC Report 2014/15: HIV Prevention on the Line, we take on the current state of global targets for the AIDS response, looking beyond pithy slogans to explore what’s in place and what’s not in terms of targets, resources and action to begin to end the AIDS epidemic. We also provide concise updates and calls to action on key prevention interventions including AIDS vaccines, voluntary medical male circumcision, microbicides, PrEP, and hormonal contraception use and HIV risk.
Intervention Update: Hormonal Contraception and HIV
Excerpted from AVAC Report: HIV Prevention on the Line, this update describes recent discussion and analysis in the search for answers as to whether hormonal contraceptives, including long-acting methods such as Depo-Provera (DPMA) and other injectable contraceptives and the implant, affect women’s risk of acquiring HIV.
Intervention Update: Voluntary Medical Male Circumcision
Excerpted from AVAC Report: HIV Prevention on the Line, this update cites the success of a previous VMMC target and suggests the current lack of a target moving forward will stifle continued progress.
Intervention Update: What’s Next for AIDS Vaccines and the P5 Partnership?
Excerpted from AVAC Report: HIV Prevention on the Line, this update details attempts to test vaccine strategy which showed promise in the RV144 trial.
Mind the Gap
This graphic, presented in the AVAC Report 2014/15: HIV Prevention on the Line, shows all the components of a comprehensive response to end the epidemic.
Targets that Worked
As seen in this graphic from AVAC Report 2014/15: HIV Prevention on the Line, ambitious coverage targets that are well-defined in terms of the components of service delivery, impact and populations and need led to success for VMMC (VMMC) and antiretroviral therapy (ART).
A Target That Worked: 3 by 5
Appearing in AVAC Report 2014/2015: HIV Prevention on the Line, this graphic shows how a target was set and met to provide ART Treatment U=U to 3 million people.